GENFIT to acquire Swiss biotech company Versantis in deal worth up to $109m
Through the deal, GENFIT will gain access to VS-01, a liposomal-based drug candidate for the treatment of acute-on-chronic…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
20 Sep 22
Through the deal, GENFIT will gain access to VS-01, a liposomal-based drug candidate for the treatment of acute-on-chronic…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
02 Sep 22
The acquisition will complement Novo Nordisk’s strategy to focus on haemoglobinopathies, a group of disorders characterised by abnormal…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
01 Sep 22
The approval is based on the data from ASCEND and ASCEND-Peds trials, in which Xenpozyme showed improvement in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
30 Aug 22
The EC approval is based on results from Phase 3 ASCEMBL trial, in which Scemblix nearly doubled the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
29 Aug 22
According to the data, Farxiga continues to provide clinically significant advantages to patients with heart failure regardless of…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Aug 22
With the planned spin-off, Sandoz will become a large-scale, independent company focused on biosimilars, antibiotics and generic medicines,…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
24 Aug 22
MK-2060 is a monoclonal antibody under development which is intended to block Factor XI's capacity to activate downstream…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Aug 22
The EC authorisation for Sunlenca is said to provide a new, every six-month treatment option for people with…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
23 Aug 22
Both companies have scaled production to deliver doses of Omicron BA.4/BA.5-adapted bivalent vaccinations and shipping after authorisation
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
22 Aug 22
Auvelity is the first and only rapid-acting oral drug approved for MDD, with a significant antidepressant efficacy compared…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates